Arcellx, Inc.
ACLX
Hisse Senetlerindeki Sıralama
#2750
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Hisse Fiyatı
$115.07
Son senkronizasyon: 2026-05-15
Piyasa Değeri
$6.73B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
38.04%
Ülke
US
Ticaret Arcellx, Inc. (ACLX)
Kategori
Healthcare
Arcellx, Inc. (ACLX) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $115.07 - 2026-05-01
Gün sonu en düşük fiyat: $17.58 - 2022-02-01
Gün sonu en düşük fiyat: $17.58 - 2022-02-01
Arcellx, Inc. için hisse fiyatı geçmişi: 2022 - 2026
Yıllık Hisse Fiyatı Performansı
| Yıl | Performans |
|---|---|
| 2026 (TTM) | 30.35% |
| 2025 | -17.00% |
| 2024 | 52.40% |
| 2023 | 93.55% |
| 2022 | 0.00% |
Benzer şirketler veya rakiplerin hisse fiyatı
| Şirket | Hisse fiyatı | Değişim 1yıl% | Ülke |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.79 | -3.81% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
